Wuxi Biologics Is a Global CRDMO With Near-Term Geopolitical Risks
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
The Biopharmaceutical Contract Manufacturing Market to Hit $38.07 Billion by 2029, Revenue to Double in the Next 6 Years – Arizton
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: The Biopharmaceutical Contract ...
Dundalk Democrat13h
Wuxi employees make generous donation to St Vincent De Paul Dundalk
WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering ...
Pharmaceutical Technology21h
Candid Therapeutics signs $925m T-cell engager deal with WuXi Biologics
Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...